Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available.
BioArctic AB will release its first quarter report for 2025 on May 21, inviting investors, analysts, and media to an audiocast and teleconference where the CEO and CFO will present and discuss the results. This event reflects BioArctic’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market perception and investor relations.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharmaceutical company specializing in innovative treatments for neurodegenerative diseases. It is known for developing Leqembi, the first drug proven to slow the progression of early Alzheimer’s disease. The company also focuses on Parkinson’s disease, ALS, and enzyme deficiency diseases, utilizing its proprietary BrainTransporter technology to enhance drug delivery to the brain. BioArctic’s B share is listed on Nasdaq Stockholm Large Cap.
Average Trading Volume: 298,636
Current Market Cap: SEK15.78B
Find detailed analytics on BIOA.B stock on TipRanks’ Stock Analysis page.